• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

血液透析中的钠浓度递增:有益和不良影响的一项研究。

Sodium ramping in hemodialysis: a study of beneficial and adverse effects.

作者信息

Sang G L, Kovithavongs C, Ulan R, Kjellstrand C M

机构信息

Department of Medicine, University of Alberta, Edmonton, Canada.

出版信息

Am J Kidney Dis. 1997 May;29(5):669-77. doi: 10.1016/s0272-6386(97)90118-9.

DOI:10.1016/s0272-6386(97)90118-9
PMID:9159299
Abstract

Sodium ramping has been introduced as a technique to decrease side effects occurring during hemodialysis. We studied sodium ramping in 414 dialysis sessions in 23 patients by randomizing 2-week blocks of dialysis to either steady dialysate sodium of 140 mEq/L, linear sodium ramping during dialysis from 155 mEq/L to 140 mEq/ L, or stepwise ramping (sodium of 155 mEq/L for 3 hours and 140 mEq/L for 1 hour). We studied the number and severity of hypotensive and hypertensive episodes. A hypotensive episode was defined as an abrupt decline of systolic blood pressure of more than 50 mm Hg, a decrease in blood pressure accompanied by symptoms requiring intervention, or systolic blood pressure of less than 90 mm Hg even without symptoms. A hypertensive episode was defined as a sudden increase in systolic blood pressure of over 30 mm Hg. We also recorded other side effects (headache, cramps, nausea, vomiting, dizziness, thirst, fatigue, weight gain, and blood pressure) during, immediately after, and between dialysis sessions. There was no major difference between the two ramping protocols, but compared with standard dialysis, both decreased total number of side effects from 4.0 to 3.0 (P = 0.057); the number of hypotensive episodes decreased from 1.3 to 0.7 (P = 0.036). The lowest blood pressure was 114/66 mm Hg during control and 123/69 mm Hg during ramping (P < 0.0001). The frequency of cramps during dialysis decreased from 0.9 to 0.5 (P = 0.006). There was no difference in headache, nausea, or vomiting. The number of hypertensive episodes increased from 0.045 to 0.086 during ramping (P = 0.125). Of 23 patients, only five (22%) had a marked decrease in symptoms; two of the three most symptomatic patients showed no significant improvement. Between dialysis sessions, patients complained of more fatigue and thirst (P < 0.0001 and P = 0.0028, respectively), and interdialytic weight gain following ramping was 5.1% of body weight compared with 4.4% without ramping (P < 0.0001). Blood pressure also increased following ramping, from 143/79 mm Hg to 152/81 mm Hg (P = 0.001). Ramping can decrease the overall number of side effects, but increases interdialytic symptoms, weight gain, and hypertension. In most instances, it simply changes the time the side effects occur. Only 22% of patients have significant benefit. These patients can be identified only through trial and error, as no model of these patients can be created.

摘要

钠浓度递增法已作为一种减少血液透析期间出现副作用的技术被引入。我们通过将为期2周的透析疗程随机分为以下三种情况,对23例患者的414次透析疗程进行了钠浓度递增法研究:透析液钠浓度稳定在140 mEq/L;透析期间钠浓度从155 mEq/L线性递增至140 mEq/L;或阶梯式递增(155 mEq/L的钠浓度持续3小时,140 mEq/L的钠浓度持续1小时)。我们研究了低血压和高血压发作的次数及严重程度。低血压发作被定义为收缩压突然下降超过50 mmHg、血压下降伴有需要干预的症状,或即使无症状收缩压低于90 mmHg。高血压发作被定义为收缩压突然升高超过30 mmHg。我们还记录了透析期间、透析刚结束后以及透析疗程之间的其他副作用(头痛、痉挛、恶心、呕吐、头晕、口渴、疲劳、体重增加和血压)。两种递增方案之间没有重大差异,但与标准透析相比,二者均使副作用总数从4.0降至3.0(P = 0.057);低血压发作次数从1.3降至0.7(P = 0.036)。对照期间最低血压为114/66 mmHg,递增期间为123/69 mmHg(P < 0.0001)。透析期间痉挛频率从0.9降至0.5(P = 0.006)。头痛、恶心或呕吐方面没有差异。递增期间高血压发作次数从0.045增至0.086(P = 0.125)。在23例患者中,只有5例(22%)症状明显减轻;症状最严重的3例患者中有2例没有显著改善。在透析疗程之间,患者抱怨更疲劳和口渴(分别为P < 0.0001和P = 0.0028),递增后透析间期体重增加为体重的5.1%,而未递增时为4.4%(P < 0.0001)。递增后血压也升高,从143/79 mmHg升至152/81 mmHg(P = 0.001)。递增法可以减少副作用的总数,但会增加透析间期症状、体重增加和高血压。在大多数情况下,它只是改变了副作用出现的时间。只有22%的患者有显著益处。由于无法建立这些患者的模型,只能通过反复试验来识别这些患者。

相似文献

1
Sodium ramping in hemodialysis: a study of beneficial and adverse effects.血液透析中的钠浓度递增:有益和不良影响的一项研究。
Am J Kidney Dis. 1997 May;29(5):669-77. doi: 10.1016/s0272-6386(97)90118-9.
2
Sodium ramping reduces hypotension and symptoms during haemodialysis.钠浓度递增可减轻血液透析期间的低血压及症状。
Hong Kong Med J. 2006 Feb;12(1):10-4.
3
Dialysate sodium delivery can alter chronic blood pressure management.透析液钠输送可改变慢性血压管理。
Am J Kidney Dis. 1997 Mar;29(3):383-91. doi: 10.1016/s0272-6386(97)90199-2.
4
Clinical consequences of an individualized dialysate sodium prescription in hemodialysis patients.血液透析患者个体化透析液钠处方的临床后果
Kidney Int. 2004 Sep;66(3):1232-8. doi: 10.1111/j.1523-1755.2004.00876.x.
5
Association between dialysate sodium concentration and interdialytic weight gain in patients undergoing twice weekly haemodialysis.在每周接受两次血液透析的患者中,透析液钠浓度与透析间期体重增加之间的关系。
BMC Nephrol. 2021 Jun 17;22(1):225. doi: 10.1186/s12882-021-02401-2.
6
Sodium modeling ameliorates intradialytic and interdialytic symptoms in young hemodialysis patients.钠模式改善年轻血液透析患者的透析期间及透析间期症状。
J Am Soc Nephrol. 1993 Nov;4(5):1192-8. doi: 10.1681/ASN.V451192.
7
Effect of gradually lowering dialysate sodium concentration on the interdialytic weight gain, blood pressure, and extracellular water in anuric hemodialysis patients.逐渐降低透析液钠浓度对无尿血液透析患者透析间体重增长、血压和细胞外液的影响。
Ren Fail. 2014 Feb;36(1):23-7. doi: 10.3109/0886022X.2013.830360. Epub 2013 Sep 2.
8
A double-blind evaluation of sodium gradient hemodialysis.钠梯度血液透析的双盲评估。
Am J Nephrol. 1985;5(3):163-8. doi: 10.1159/000166927.
9
Increasing the dialysate sodium concentration based on serum sodium concentrations exacerbates weight gain and thirst in hemodialysis patients.基于血清钠浓度增加透析液钠浓度会加重血液透析患者的体重增加和口渴。
Tohoku J Exp Med. 2013 Jun;230(2):117-21. doi: 10.1620/tjem.230.117.
10
Dialysate sodium and sodium gradient in maintenance hemodialysis: a neglected sodium restriction approach?维持性血液透析中透析液钠和钠梯度:被忽视的钠限制方法?
Nephrol Dial Transplant. 2011 Apr;26(4):1281-7. doi: 10.1093/ndt/gfq807. Epub 2011 Feb 8.

引用本文的文献

1
Low dialysate sodium levels for chronic haemodialysis.慢性血液透析中低透析液钠水平。
Cochrane Database Syst Rev. 2024 Nov 5;11(11):CD011204. doi: 10.1002/14651858.CD011204.pub3.
2
Interventions for fatigue in people with kidney failure requiring dialysis.肾衰竭需透析患者的疲劳干预措施。
Cochrane Database Syst Rev. 2023 Aug 31;8(8):CD013074. doi: 10.1002/14651858.CD013074.pub2.
3
Fatigue in Patients Receiving Maintenance Hemodialysis: A Review.维持性血液透析患者的疲劳:综述。
Am J Kidney Dis. 2023 Oct;82(4):464-480. doi: 10.1053/j.ajkd.2023.02.008. Epub 2023 May 13.
4
Dialysis recovery time: associated factors and its association with quality of life of hemodialysis patients.透析恢复时间:相关因素及其与血液透析患者生活质量的关系。
BMC Nephrol. 2022 Sep 1;23(1):298. doi: 10.1186/s12882-022-02926-0.
5
Effect of ultrafiltration profiling on outcomes among maintenance hemodialysis patients: a pilot randomized crossover trial.超滤曲线对维持性血液透析患者结局的影响:一项初步的随机交叉试验。
J Nephrol. 2021 Feb;34(1):113-123. doi: 10.1007/s40620-020-00862-6. Epub 2020 Sep 25.
6
Ultrafiltration-profiled hemodialysis to reduce dialysis-related cardiovascular stress: Study protocol for a randomized controlled trial.超滤模式血液透析以减轻透析相关心血管应激:一项随机对照试验的研究方案
Contemp Clin Trials Commun. 2019 Jul 19;15:100415. doi: 10.1016/j.conctc.2019.100415. eCollection 2019 Sep.
7
Low dialysate sodium levels for chronic haemodialysis.慢性血液透析的低透析液钠水平
Cochrane Database Syst Rev. 2019 Jan 16;1(1):CD011204. doi: 10.1002/14651858.CD011204.pub2.
8
Osmolality and blood pressure stability during hemodialysis.血液透析期间的渗透压和血压稳定性。
Semin Dial. 2017 Nov;30(6):509-517. doi: 10.1111/sdi.12629. Epub 2017 Jul 9.
9
Setting the dry weight and its cardiovascular implications.设定干体重及其对心血管系统的影响。
Semin Dial. 2017 Nov;30(6):481-488. doi: 10.1111/sdi.12624. Epub 2017 Jun 30.
10
Dialysate Sodium: Rationale for Evolution over Time.透析液钠:随时间演变的原理
Semin Dial. 2017 Mar;30(2):99-111. doi: 10.1111/sdi.12570. Epub 2017 Jan 8.